Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hyperkalemia is a frequent, serious complication in patients with chronic kidney disease (CKD) and heart failure (HF).
• Elevated potassium levels impede the optimal use of renin-angiotensin-aldosterone system inhibitors (RAASi), medications vital for cardiorenal health.
• Current guidelines stress normokalemia to facilitate RAASi therapy, crucial for managing hypertensive kidney disease.

Purpose of the Study:

• To review the role of sodium zirconium cyclosilicate (SZC) in managing hyperkalemia.
• To reposition hyperkalemia as a treatable barrier to guideline-directed cardiorenal therapies.
• To summarize SZC's pharmacology, clinical evidence, and practical use in high-risk patients.

Main Methods:

• Review of current literature and clinical guidelines.
• Analysis of pharmacological properties of sodium zirconium cyclosilicate.
• Synthesis of clinical trial data on SZC efficacy and safety.

Main Results:

• Sodium zirconium cyclosilicate effectively reduces and controls serum potassium levels.
• SZC facilitates the initiation and maintenance of RAASi therapy in patients with hyperkalemia.
• Evidence supports SZC's role in improving cardiorenal outcomes by enabling guideline-directed care.

Conclusions:

• Hyperkalemia is a modifiable factor hindering optimal cardiorenal treatment.
• Sodium zirconium cyclosilicate is a valuable therapeutic option for managing hyperkalemia.
• SZC use supports adherence to guideline-directed therapy, improving outcomes for high-risk patients.